GlobeNewsWire
14 Aug 2026, 19:37 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. — A negative advisory committee vote significantly decreases the probability of FDA approval for a company's lead product candidate.
-0.90The FDA stated that the benefit-risk assessment for Deramiocel appeared unfavorable in the absence of evidence of effectiveness. — Direct negative feedback from the regulator regarding the benefit-risk profile is a critical hurdle for commercialization.
-0.80The FDA identified that Capricor made changes to its statistical analysis plan (SAP) that were not agreed upon by the agency prior to the BLA submission. — Unauthorized changes to analysis plans lead to data being labeled as 'post-hoc,' which undermines the scientific validity of trial results.
-0.60Continue reading
6 related stories
Top 1 mover · tap to explore
A securities class action lawsuit has been filed alleging Capricor misled investors regarding the path to FDA approval for Deramiocel. — Legal liabilities and class action suits create additional financial risk and management distraction.
-0.30Which stocks this story touches
The company is facing a securities class action lawsuit following a 64% stock drop and negative FDA advisory committee feedback regarding its lead product candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
